Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGR018: NGR-hTNF plus anthracycline versus anthracycline alone in platinum-resistant ovarian cancer
2012-005745-20Phase 2Completed
- Sponsor
- AGC Biologics
- Start
- Feb 2013
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of NGR-TNF in ovarian cancer (2 arms), sponsored by AGC Biologics. Primary endpoint: Early safety of weekly NGR-hTNF. Started Feb 2013; status: completed.
02
Drugs
NGR-TNF
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2012-005745-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005745-20.